Dr. Erin K. Crane, MD

Dr. Crane practices at Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health.

Dr. Crane's NPI, 1750594800, was assigned on May 7, 2007. Dr. Crane holds North Carolina license 2014-01492.

Dr. Crane's primary practice is Atrium Health Carolinas Medical Center, at 1000 Blythe Blvd, Charlotte, NC 28203 in Mecklenburg County. The practice phone is (704) 355-2000.

Dr. Crane's primary practice is Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health. Dr. Crane is also affiliated with Atrium Health Pineville. The medical group on file is Atrium Health Levine Children's Gastroenterology. Dmand AI also links Dr. Crane to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crane practices, 6 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Crane's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Crane is licensed in North Carolina.

CMS data shows 318 Medicare services from Dr. Crane across 6 procedure codes in 2024, for 184 Medicare patients. Medicare paid $30,392 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 184 Medicare patients who saw Dr. Crane in 2024. The largest group is 65 to 74, with 107 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Crane's median patient age at 71, with 99% women.

In 2024, Dr. Crane wrote 486 Medicare Part D claims for 128 patients. 84% of them were for generic drugs. CMS names the drug for 287 of them, across 12 drugs with 11 or more claims each, at $374,136 in total drug cost. In 2023, CMS named 291 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Crane for performance year 2024, reported through an alternative payment model (APM). Dr. Crane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Crane as offering telehealth. CMS counts 14 procedures of removal of the uterus by Dr. Crane, more than 88% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 30 papers to Dr. Crane, published from 2013 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Ovarian Neoplasms, Laparoscopy and Endometrial Neoplasms. Dr. Crane has published most often in Gynecol Oncol. Dr. Crane's most frequent co-authors are Jubilee Brown, MD, David Loren Tait, MD and Robert Wendel Naumann, MD.

Dmand AI links Dr. Crane to 6 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Uterine Cervical Neoplasms. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 74 general payments to Dr. Crane from 13 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. GlaxoSmithKline, LLC. paid the most, $48,263.